Search





Search





Markets
/
Stocks
/
sabs
/

SAB Biotherapeutics Inc

SABS

Add to Watchlist

3.570USD

+0.010+0.28%

Close 07-31 16:00（ET）Quotes delayed by 15 min

272.98MMarket Cap

8.35P/E TTM

SAB Biotherapeutics Inc

3.570

+0.010+0.28%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

SABS Cash Flow Statement

You can access the annual and quarterly cash flow statements of SAB Biotherapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

Operating cash flows (indirect method)

Cash flow from continuing operating activities

-83.03%-14.27M

-76.00%-16.78M

-107.41%-13.05M

7.34%-7.15M

27.47%-7.80M

29.11%-9.53M

-21.75%-6.29M

-57.53%-7.72M

-569.48%-10.75M

-6304.59%-13.45M

19.28%-5.17M

5.95%-4.90M

83.16%-1.61M

-91.47%216.72K

-7098.79%-6.40M

-5044.68%-5.21M

-2526.32%-9.54M

--2.54M

---88.93K

---101.25K

---363.16K

Net income from continuing operations

-263.09%-18.87M

-47.97%-16.86M

539.11%45.45M

-37.88%-10.11M

-3.40%-5.20M

50.15%-11.39M

-102.84%-10.35M

-6.61%-7.34M

31.66%-5.03M

-190.26%-22.86M

27.89%-5.10M

-44.07%-6.88M

-845.93%-7.35M

55.22%-7.87M

-2038.89%-7.08M

-116.88%-4.78M

-66.84%985.86K

---17.58M

---330.83K

---2.20M

--2.97M

Operating gains losses

-3.29%752.67K

-2.85%763.30K

-20.83%765.47K

-26.61%774.52K

-60.79%778.30K

-16.80%785.71K

-1.89%966.86K

18.27%1.06M

114.99%1.98M

2.26%944.40K

8.30%985.45K

14.25%892.27K

36.27%923.17K

-44.15%923.52K

--909.91K

--781.00K

--677.44K

--1.65M

----

Deferred tax

----

-100.00%0.00

----

---92.28K

--92.28K

----

Other non-cash items

109.60%485.51K

52.06%3.48M

-112912.98%-61.62M

126.86%618.46K

8.95%-5.06M

-53.25%2.29M

69.50%-54.53K

-664.98%-2.30M

-50832.94%-5.55M

7211.35%4.89M

77.17%-178.76K

123.55%407.52K

100.14%10.94K

-101.97%-68.79K

---782.96K

---1.73M

---7.85M

--3.49M

----

Change in working capital

-293.57%-2.06M

-288.27%-7.32M

-22.54%1.62M

258.02%942.80K

138.37%1.06M

-340.88%-1.88M

240.24%2.10M

609.17%263.34K

-165.88%-2.77M

-106.47%-427.41K

-4975.96%-1.49M

-3.30%37.13K

197.32%4.21M

-42.70%6.61M

-111.94%-29.45K

-75.32%38.40K

-1620.18%-4.33M

--11.53M

--246.62K

--155.59K

---251.55K

-Change in receivables

----

-100.00%0.00

110.86%361.74K

-81.53%401.39K

226.95%4.79M

-41.19%7.39M

---3.33M

--2.17M

---3.78M

--12.56M

----

-Change in prepaid expenses

-2.13%-297.26K

-612.67%-6.86M

8348.53%2.13M

-138.11%-262.20K

-0.53%-291.07K

31.79%-963.01K

-111.21%-25.84K

103.06%687.93K

-190.79%-289.54K

-215.79%-1.41M

-90.47%230.56K

515.44%338.79K

189.93%318.90K

205.31%1.22M

3036.41%2.42M

-198.59%-81.55K

-36.22%-354.61K

---1.16M

--77.13K

--82.72K

---260.32K

-Change in other current liabilities

----

62.40%-114.70K

100.00%0.00

-492.42%-263.14K

-132.14%-944.58K

---305.01K

---1.27M

---44.42K

3039.20%2.94M

--0.00

---100.00K

----

Cash from non-recurring investing activities

Cash from operating activities

-83.03%-14.27M

-76.00%-16.78M

-107.41%-13.05M

7.34%-7.15M

27.47%-7.80M

29.11%-9.53M

-21.75%-6.29M

-57.53%-7.72M

-569.48%-10.75M

-6304.59%-13.45M

19.28%-5.17M

5.95%-4.90M

83.16%-1.61M

-91.47%216.72K

-7098.79%-6.40M

-5044.68%-5.21M

-2526.32%-9.54M

--2.54M

---88.93K

---101.25K

---363.16K

Investing cash flow

Net cash from continuing investing activities

196308.00%981.04K

1585.10%933.16K

-100.00%0.00

-100.39%-500.00

-18.40%55.38K

145.50%100.30K

131.49%52.51K

505.98%129.07K

-42.37%67.86K

-47.96%40.86K

-96.30%22.68K

-98.34%21.30K

-98.92%117.75K

--78.50K

--612.83K

--1.28M

--10.94M

----

Capital expenditures

--983.26K

1585.10%933.16K

----

-18.40%55.38K

17.58%100.30K

131.49%52.51K

505.98%129.07K

-42.37%67.86K

8.66%85.31K

-96.30%22.68K

-98.43%21.30K

-98.92%117.75K

--78.50K

--612.83K

--1.36M

--10.94M

----

Net cash flow from disposal of fixed assets

196308.00%981.04K

1585.10%933.16K

-100.00%0.00

-100.39%-500.00

-18.40%55.38K

145.50%100.30K

131.49%52.51K

505.98%129.07K

-42.37%67.86K

-47.96%40.86K

-96.30%22.68K

-98.34%21.30K

-98.92%117.75K

--78.50K

--612.83K

--1.28M

--10.94M

----

Net cash flow from investment products

-1484.55%-64.67M

-108.24%-773.00K

-12240.93%-129.87M

-53.88%5.20M

114.96%4.67M

--9.39M

---1.05M

--11.27M

---31.23M

----

--0.00

---116.15M

Net cash flow from other investing activities

--0.00

----

--0.00

----

--116.15M

----

Cash from non-current investing activities

Net cash flow from investing activities

-1505.40%-65.65M

-118.29%-1.71M

-11167.05%-129.87M

-53.67%5.20M

114.90%4.67M

13849.21%9.33M

-2721.23%-1.15M

49556.96%11.22M

-147126.32%-31.36M

42.37%-67.86K

47.96%-40.86K

96.30%-22.68K

98.34%-21.30K

-100.11%-117.75K

---78.50K

---612.83K

98.90%-1.28M

--105.21M

--0.00

---116.15M

Financing cash flow

Cash flow from continuous financing activities

51783.26%89.92M

-119.21%-41.69K

25123.21%168.69M

45.85%-173.84K

55.89%-173.99K

-99.68%216.96K

-380.46%-674.13K

11.75%-321.04K

-9.62%-394.42K

922.37%67.64M

92.22%-140.31K

-1312.30%-363.79K

94.31%-359.79K

108.13%6.62M

---1.80M

--30.01K

-105.39%-6.32M

---81.39M

--0.00

--117.29M

Net cash flow from debt Issuance/repayment

78.25%-37.39K

-115.16%-36.67K

94.46%-35.98K

31.10%-173.84K

30.52%-171.91K

-49.37%241.90K

-354.77%-649.13K

30.64%-252.33K

31.59%-247.44K

144.86%477.76K

92.09%-142.74K

-829.62%-363.79K

55.04%-361.68K

-162.86%-1.07M

---1.80M

---39.13K

-436.36%-804.53K

--1.69M

--0.00

---150.00K

Net cash flow from common stock issuance/repurchase

--86.87M

----

-100.00%0.00

--0.00

100.00%0.00

-77.63%7.68M

--0.00

-104.69%-5.52M

--34.34M

--0.00

--117.64M

Net cash flow from preferred stock issuance/repurchase

----

--0.00

--168.73M

----

Proceeds from stock option exercised by employees

--113.12K

----

-100.00%-3.00

-100.00%0.00

--0.00

980.00%20.41K

5965926300.00%59.66M

242900.00%2.43K

-100.00%0.00

-75.86%1.89K

-100.01%-1.00

--1.00

--69.14K

--7.83K

--6.75K

----

Proceeds from issuance of warrants

--2.98M

----

--7.50M

----

Net cash flow from other financing activities

-120.61%-4.57K

79.90%-5.01K

80.48%-4.88K

100.00%0.00

98.76%-2.07K

---24.93K

---25.00K

---68.71K

---167.39K

----

---117.44M

--0.00

---208.23K

Net cash from non-recurrent financing activities

Net cash from financing activities

51783.26%89.92M

-119.21%-41.69K

25123.21%168.69M

45.85%-173.84K

55.89%-173.99K

-99.68%216.96K

-380.46%-674.13K

11.75%-321.04K

-9.62%-394.42K

922.37%67.64M

92.22%-140.31K

-1312.30%-363.79K

94.31%-359.79K

108.13%6.62M

---1.80M

--30.01K

-105.39%-6.32M

---81.39M

--0.00

--117.29M

Net cash flow

Beginning cash balance

18.03%10.50M

220.84%29.42M

-78.59%3.69M

-59.81%5.64M

-84.27%8.90M

278.12%9.17M

121.78%17.24M

7.46%14.03M

275.93%56.57M

-70.89%2.43M

-53.21%7.77M

-41.72%13.06M

-61.95%15.05M

-36.85%8.33M

2095.62%16.62M

2511.54%22.41M

46513.49%39.55M

--13.19M

--756.80K

--858.05K

--84.84K

Current period cash flow changes

407.50%10.02M

-6825.84%-18.92M

418.82%25.73M

-160.72%-1.95M

92.34%-3.26M

-100.50%-273.21K

-50.89%-8.07M

160.70%3.21M

-2040.72%-42.53M

706.30%54.14M

35.43%-5.35M

8.74%-5.29M

88.41%-1.99M

-74.52%6.71M

-9215.53%-8.28M

-5620.30%-5.79M

-2316.27%-17.14M

--26.35M

---88.93K

---101.25K

--773.22K

Effect of exchange rate changes

-65.34%14.73K

-37.79%-397.86K

-178.96%-37.54K

534.31%179.40K

250.34%42.50K

-1691.42%-288.75K

--47.54K

--28.28K

---28.27K

--18.14K

----

Ending cash balance

263.80%20.52M

18.03%10.50M

220.84%29.42M

-78.59%3.69M

-59.81%5.64M

-84.27%8.90M

278.12%9.17M

121.78%17.24M

7.46%14.03M

275.93%56.57M

-70.89%2.43M

-53.21%7.77M

-41.72%13.06M

-61.95%15.05M

1147.57%8.33M

2095.62%16.62M

2511.54%22.41M

--39.55M

--667.87K

--756.80K

--858.05K

Free cash flow

-95.64%-15.25M

-84.71%-17.71M

-104.15%-13.05M

7.96%-7.15M

28.33%-7.80M

29.06%-9.59M

-21.69%-6.39M

-57.87%-7.77M

-568.65%-10.88M

-13755.51%-13.51M

18.94%-5.25M

15.46%-4.92M

85.07%-1.63M

101.18%98.97K

-7187.07%-6.48M

-5649.93%-5.82M

-2900.08%-10.90M

---8.40M

---88.93K

---101.25K

---363.16K

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did SAB Biotherapeutics Inc Generate?



SAB Biotherapeutics Inc generated -44.78M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did SAB Biotherapeutics Inc's Operating Cash Flow Change Year Over Year?



SAB Biotherapeutics Inc's operating cash flow increased by -30.57% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does SAB Biotherapeutics Inc Spend on Capital Expenditures?



SAB Biotherapeutics Inc spent 933.16K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has SAB Biotherapeutics Inc's Financing Cash Flow Changed?



SAB Biotherapeutics Inc used 168.30M in financing activities in the latest quarter.

What is free cash flow and why does it matter for SABS?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was SAB Biotherapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -45.71M reflecting a -31.99% change from the previous year.